Mitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice

International Immunopharmacology

Volumn 10, Issue 4, 2010, Pages 540-545

  Nakai, Noriaki ^a   Kishida, Tsunao ^a   Hartmann, Gunther ^b   Katoh, Norito ^a   Imanishi, Jiro ^a   Kishimoto, Saburo ^a   Mazda, Osam ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Electroporation; Immunotherapy; Interleukin 12; Melanoma; RNA interference

Indexed keywords

INTERLEUKIN 12; MELANIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ELECTROPORATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; IN VIVO STUDY; MELANOCYTE; MELANOGENESIS; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; DNA; ELECTROPORATION; FEMALE; GENE SILENCING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77949488331     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.12.015     Document Type: Article

References (46)

1. Ibrahim N., and Haluska F.G. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 4 (2009) 551-579
2. Tuettenberg A., Schmitt E., Knop J., and Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges 5 (2007) 190-196
3. Nakai N., Katoh N., Kitagawa T., Ueda E., Takenaka H., and Kishimoto S. Evaluation of survival in Japanese stage IV melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cells. J Dermatol 35 (2008) 801-803
4. Lesterhuis W.J., Aarntzen E.H., De Vries I.J., Schuurhuis D.H., Figdor C.G., Adema G.J., et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 66 (2008) 118-134
5. Davis I., and Fisher D.E. MiT transcription factor associated malignancies in man. Cell Cycle 6 (2007) 1724-1729
6. Mitra D., and Fisher D.E. Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 23 (2009) 447-465 viii
7. McGill G.G., Horstmann M., Widlund H.R., Du J., Motyckova G., Nishimura E.K., et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109 (2002) 707-718
8. McGill G.G., Haq R., Nishimura E.K., and Fisher D.E. c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281 (2006) 10365-10373
9. Du J., Widlund H.R., Horstmann M.A., Ramaswamy S., Ross K., Huber W.E., et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6 (2004) 565-576
10. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
11. Busca R., Berra E., Gaggioli C., Khaled M., Bille K., Marchetti B., et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170 (2005) 49-59
12. Vance K.W., Carreira S., Brosch G., and Goding C.R. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 65 (2005) 2260-2268
13. Carreira S., Goodall J., Aksan I., La Rocca S.A., Galibert M.D., Denat L., et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433 (2005) 764-769
14. Loercher A.E., Tank E.M., Delston R.B., and Harbour J.W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168 (2005) 35-40
15. Selzer E., Wacheck V., Lucas T., Heere-Ress E., Wu M., Weilbaecher K.N., et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 62 (2002) 2098-2103
16. Wellbrock C., and Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170 (2005) 703-708
17. Larribere L., Hilmi C., Khaled M., Gaggioli C., Bille K., Auberger P., et al. The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 19 (2005) 1980-1985
18. Nakai N., Kishida T., Shin-Ya M., Imanishi J., Ueda Y., Kishimoto S., et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 14 (2007) 357-365
19. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13 (2007) 4677-4685
20. Kanagawa N., Gao J.Q., Motomura Y., Yanagawa T., Mukai Y., Yoshioka Y., et al. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor. Biochem Biophys Res Commun 372 (2008) 821-825
21. Cavallo F., Quaglino E., Cifaldi L., Di Carlo E., Andre A., Bernabei P., et al. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res 61 (2001) 3518-3523
22. Strasly M., Cavallo F., Geuna M., Mitola S., Colombo M.P., Forni G., et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166 (2001) 3890-3899
23. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., and Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93 (1999) 1612-1621
24. Kishida T., Asada H., Satoh E., Tanaka S., Shinya M., Hirai H., et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 8 (2001) 1234-1240
25. Lohr F., Lo D.Y., D.A. Z., Hu K., Zhang X., Li Y., et al. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 61 (2001) 3281-3284
26. Lucas M.L., Heller L., Coppola D., and Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5 (2002) 668-6675
27. Yamashita Y.I., Shimada M., Hasegawa H., Minagawa R., Rikimaru T., Hamatsu T., et al. Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61 (2001) 1005-1012
28. Tamura T., Nishi T., Goto T., Takeshima H., Dev S.B., Ushio Y., et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther 12 (2001) 1265-1276
29. Lucas M.L., and Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 22 (2003) 755-763
30. Xenidis N., Kotsakis A., Kalykaki A., Christophyllakis C., Giassas S., Kentepozidis N., et al. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer. A multicenter phase II study. Lung Cancer (2009)
31. Gofrit O.N., Shapiro A., Pode D., Sidi A., Nativ O., Leib Z., et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63 (2004) 466-471
32. Kishida T., Asada H., Gojo S., Ohashi S., Shin-Ya M., Yasutomi K., et al. Sequence-specific gene silencing in murine muscle induced by electroporation-mediated transfer of short interfering RNA. J Gene Med 6 (2004) 105-110
33. Osaki T., Hashimoto W., Gambotto A., Okamura H., Robbins P.D., Kurimoto M., et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 6 (1999) 808-815
34. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
35. Yates J.L., Waren N., and Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 (1985) 812-815
36. Asada H., Kishida T., Hirai H., Satoh E., Ohashi S., Takeuchi M., et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther 5 (2002) 609-616
37. Asada H., Kishida T., Hirai H., Shin-Ya M., Imanishi J., Takeuchi M., et al. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Cancer Lett 240 (2006) 83-93
38. Levy C., Khaled M., and Fisher D.E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12 (2006) 406-414
39. Castanotto D., and Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457 (2009) 426-433
40. Andre F., and Mir L.M. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 11 Suppl 1 (2004) S33-S42
41. Ohashi S., Kubo T., Kishida T., Ikeda T., Takahashi K., Arai Y., et al. Successful genetic transduction in vivo into synovium by means of electroporation. Biochem Biophys Res Commun 293 (2002) 1530-1535
42. Kishida T., Asada H., Itokawa Y., Yasutomi K., Shin-Ya M., Gojo S., et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 8 (2003) 738-745
43. Inoue A., Takahashi K.A., Mazda O., Terauchi R., Arai Y., Kishida T., et al. Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun 336 (2005) 903-908
44. Inoue A., Takahashi K.A., Mazda O., Arai Y., Saito M., Kishida T., et al. Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets. Mod Rheumatol 19 (2009) 125-133
45. Sersa G., Cemazar M., and Snoj M. Electrochemotherapy of tumours. Curr Oncol 16 (2009) 34-35
46. Daud A.I., DeConti R.C., Andrews S., Urbas P., Riker A.I., Sondak V.K., et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26 (2008) 5896-5903